The estimated Net Worth of Richard J Hawkins is at least $21.2 Tausend dollars as of 8 May 2024. Mr. Hawkins owns over 4,902 units of Savara Inc stock worth over $21,181 and over the last 17 years he sold SVRA stock worth over $0. In addition, he makes $0 as Independent Director at Savara Inc.
Sign up
Mr. Hawkins SVRA stock SEC Form 4 insiders trading
Richard has made over 7 trades of the Savara Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 4,902 units of SVRA stock worth $10,000 on 8 May 2024.
The largest trade he's ever made was exercising 120,000 units of Savara Inc stock on 12 August 2016 worth over $288,000. On average, Richard trades about 4,647 units every 81 days since 2007. As of 8 May 2024 he still owns at least 4,903 units of Savara Inc stock.
You can see the complete history of Mr. Hawkins stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard Hawkins biography
Richard J. Hawkins serves as Independent Director of the Company. Mr. Hawkins has served as a member of our Board of Directors since October 2010. Mr. Hawkins is currently the President, Chief Executive Officer and Chairman of Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical stage biotechnology company focused on bringing novel therapies to patients with severe, rare, and genetic diseases, whose medical needs are unmet. In addition, Mr. Hawkins currently serves on the board of directors of several privately held life sciences companies, as well as Plus Therapeutics Inc. (formerly Cytori Therapeutics, Inc.) (NASDAQ: PSTV), and previously served on the board of directors of SciClone Pharmaceuticals, Inc. until its acquisition in October 2017. Prior to his tenure with Lumos Pharma, Inc., which began in September 2010, Mr. Hawkins, founded and advised numerous pharmaceutical companies including Sensus, where he served as co-founder and Chairman until it was sold to Pfizer. From 1981 to 2000, Mr. Hawkins was founder, President and CEO of Pharmaco and guided the company’s growth to over 2,000 employees. The company later merged with PPD of Wilmington, NC to form PPD Pharmaco, one of the largest clinical contract research organizations in the world. Mr. Hawkins received his Bachelor of Science in Biology from Ohio University.
How old is Richard Hawkins?
Richard Hawkins is 71, he's been the Independent Director of Savara Inc since 2017. There are no older and 11 younger executives at Savara Inc.
What's Richard Hawkins's mailing address?
Richard's mailing address filed with the SEC is C/O PLUS THERAPEUTICS INC., 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN, TX, 78756.
Insiders trading at Savara Inc
Over the last 7 years, insiders at Savara Inc have traded over $2,203,958 worth of Savara Inc stock and bought 6,103,761 units worth $15,290,245 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, Savara Inc executives and independent directors trade stock every 29 days with the average trade being worth of $348,922. The most recent stock trade was executed by Matthew Pauls on 28 December 2023, trading 84,000 units of SVRA stock currently worth $395,640.
What does Savara Inc do?
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
What does Savara Inc's logo look like?
Complete history of Mr. Hawkins stock trades at Savara Inc und Plus Therapeutics
Savara Inc executives and stock owners
Savara Inc executives and other stock owners filed with the SEC include:
-
Dr. Badrul A. Chowdhury M.D., Ph.D.,
Chief Medical Officer -
David Lowrance,
Chief Financial Officer, Secretary -
David L. Lowrance,
CFO & Sec. -
Ricky Sun,
Independent Director -
Annigje van Es-Johansson,
Independent Director -
Badrul Chowdhury,
Chief Medical Officer -
Anne Erickson,
IR Contact Officer -
David Ramsay,
Independent Director -
Matthew Pauls,
Chairman of the Board, Interim Chief Executive Officer -
Joseph McCracken,
Independent Director -
Richard Hawkins,
Independent Director -
Nevan Elam,
Independent Director -
Dr. Peter Clarke Ph.D.,
Exec. VP of Global Technical Operations -
Charles LaPree,
Sr. VP of Global Regulatory Affairs & Quality Assurance -
Brian Maurer,
Head of Clinical Operations -
Dr. Dhaval Desai M.D.,
Head of Clinical Devel. -
Kate McCabe,
Sr. VP of Legal Affairs -
Robert N Neville,
Chief Executive Officer -
Yuri Pikover,
Director -
Jaakko Taneli Jouhikainen,
See Remarks -
Es Johansson An Van,
Director -
Forest Baskett,
10% owner -
Equity Opportunities 17, Ll...,
-
Rick Yang,
10% owner -
Paul Edward Walker,
10% owner -
Scott D Sandell,
10% owner -
Edward T Mathers,
10% owner -
Mohamad Makhzoumi,
10% owner -
Carmen Chang,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Ali Behbahani,
10% owner -
Raymond Dennis Pratt,
Chief Medical Officer -
Robert Matthew Lutz,
Chief Operating Officer